Trials

BIBF1120 in patient with glioblastoma and progression after standard therapy /temozolomide and radiotherapy (group 1) or after bevacizumab based secondline therapy (group 2)

Cancer type: Glioblastoma

Phase: II

Principal Investigator: Lassen Ulrik

Country: DK

Keywords: Denmark, Rigshospitalet, GBM, angiogenesis inhibition

Status: Completed

Link to Clinicaltrials.gov: http://www.clinicaltrials.gov/ct2/show/NCT01251484?term=NCT01251484&rank=1